AestheticsHormonesSex & FertilitySubcutaneous

Melanotan II

Typical Dose

0.25–1 mg

Frequency

Daily during loading

Half-Life

~1 hour

Research-use dosing; specific study population not established.

Melanotan II Overview

Mechanism of Action

Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that binds to melanocortin receptors (MC1R through MC5R). MC1R activation stimulates melanogenesis (melanin production) in skin cells, producing a tan without UV exposure. MC3R/MC4R activation mediates appetite suppression and sexual arousal effects.

Half-Life

~1 hour

Timing

Evening (nausea is less noticeable during sleep)

Injection Site

Subcutaneous, abdomen

Food

Light stomach preferred; nausea more likely on full stomach

Common Stacks

  • Standalone use most common

Melanotan II Dosing Protocol

Loading Phase

2–3 weeks

250–500 mcg daily

Start at 250 mcg to assess tolerance. Gradually increase.

Maintenance

As desired

500–1000 mcg 1–2x/week

Maintain achieved pigmentation with periodic dosing.

Melanotan II Expected Timeline

Week 1

Facial flushing; possible nausea

Week 2–3

Visible skin darkening begins

Week 4–6

Full tan effect; maintenance dosing begins

Melanotan II Side Effects

Nausea (common at initiation, decreases with use)

Facial flushing

Appetite suppression

Mole darkening (monitor existing moles)

Spontaneous erections

Melanotan II Research Studies

Superpotent melanotropin 4-10 derivative: mechanism of action

Hruby VJ, Lu D, Sharma SD, et al. — Ann N Y Acad Sci (1999)

Described the development and mechanism of Melanotan II as a superpotent melanocortin receptor agonist, establishing its pharmacological profile across multiple receptor subtypes.

PubMed: 10681895

Melanotan II FAQ

Do I still need sun exposure?

Melanotan II stimulates melanin production, but some UV exposure (even brief) helps activate and distribute the melanin for a more even tan. Many users combine minimal sun exposure with MT2 for best results.

Why do moles darken?

Melanocytes in moles are especially responsive to melanocortin stimulation. Mole darkening is expected but should be monitored. Report any asymmetric changes, border irregularity, or rapid growth to a dermatologist.

Related Protocols